Skip to main content

DayOne gains importance

| News

DayOne gains importance

08.08.2019

DayOne, a BaselArea.swiss initiative, is creating a world-leading healthcare innovation hub based on the strengths of the Basel region. A further important partner has joined to help achieve this goal.

The Department of Biosystems (D-BSSE) in Basel, which is part of the Federal Institute of Technology in Zurich (ETH), has become the latest partner of DayOne, according to a statement. With the partnership, the department will help promote digital healthcare applications and create a world-leading center for precision medicine.

Its goals are in line with those of BaselArea.swiss, which operates the DayOne initiative. BaselArea.swiss has access to sector and technology experts, doctors and scientists, and is planning to exploit the know-how of around 2,000 healthcare innovators currently based in the Basel region.

The initiative DayOne has six core activities – among them supporting the existing network, launching pioneering projects and providing collaborative workspaces. Another aspect is helping companies from abroad to settle in the Basel region, which BaselArea.swiss specializes in. Furthermore the initiative announced news concerning the other two core activities.

On September 9, the next DayOne Conference will be held at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) in Muttenz in the canton of Basel-Landschaft. Entitled “Shaping the Future of Health”, the conference is expected to attract around 400 innovators, patients and experts. It will look at topics including digitalization and ethics, and will showcase innovations from the DayOne Accelerator and others.

The accelerator is the initiative’s sixth core activity. BaselArea.swiss and the partner organizations received more than 150 applications for the accelerator, twice as many as last year. The 16 companies considered for the first round of the accelerator can present their projects at the DayOne Conference. Four companies will then be selected for funding under the accelerator from January 2020.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.